Glaukos develops micro-invasive ophthalmic devices and therapies, best known for iStent and related implants that help lower intraocular pressure in glaucoma by improving aqueous outflow. The portfolio has expanded into corneal health and other interventional eye treatments beyond traditional eye drops alone. Its customers are primarily ophthalmologists and surgical centers treating progressive glaucoma and related anterior-segment disease.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 124.1 | — | -19.7 | — |
| Q3 2025 | 133.5 | — | -16.2 | — |
| Q4 2025 | 143.1 | — | -133.7 | — |
| Q1 2026 | 150.6 | — | -19.8 | — |
| Q2 2026 | 185.6 | 49.5% | -18.4 | — |
All markets — KeepWinning global stock screener
Other companies on NYSE: Companhia Energética de Minas Gerais - CEMIG (CIG C), Darling Ingredients Inc. (DAR), Advanced Drainage Systems, Inc. (WMS), Cullen/Frost Bankers, Inc. (CFR), Elastic N.V. (ESTC), Old Republic International Corporation (ORI)